Effective Date of Rule: Thirty-one days after filing.

     Purpose: WAC 246-887-100 adds synthetic cannabinoids and substituted cathinones to Schedule I of the Controlled Substances Act. Synthetic cannabinoids are sold as incense and are most commonly known as Spice. Substituted cathinones are sold as bath salts and are known by names like Ivory Wave and Zoom. The rule gives law enforcement clear authority to prosecute for the sale, possession, manufacture and delivery of these substances.

     Citation of Existing Rules Affected by this Order: Amending WAC 246-887-100.

     Statutory Authority for Adoption: RCW 18.64.005.

     Other Authority: RCW 69.50.201 and 69.50.203.

      Adopted under notice filed as WSR 11-16-040 on July 27, 2011.

     A final cost-benefit analysis is available by contacting Kitty Slater-Einert, P.O. Box 47863, Olympia, WA 98504-7863, phone (360) 236-4861, fax (360) 236-2901, e-mail kitty.slater@doh.wa.gov.

     Number of Sections Adopted in Order to Comply with Federal Statute: New 0, Amended 0, Repealed 0; Federal Rules or Standards: New 0, Amended 1, Repealed 0; or Recently Enacted State Statutes: New 0, Amended 0, Repealed 0.

     Number of Sections Adopted at Request of a Nongovernmental Entity: New 0, Amended 0, Repealed 0.

     Number of Sections Adopted on the Agency's Own Initiative: New 0, Amended 1, Repealed 0.

     Number of Sections Adopted in Order to Clarify, Streamline, or Reform Agency Procedures: New 0, Amended 0, Repealed 0.

     Number of Sections Adopted Using Negotiated Rule Making: New 0, Amended 0, Repealed 0;      Pilot Rule Making: New 0, Amended 0, Repealed 0; or Other Alternative Rule Making: New 0, Amended 1, Repealed 0.

     Date Adopted: September 8, 2011.

A. J. Linggi, Chair

Board of Pharmacy

OTS-3833.4

AMENDATORY SECTION(Amending WSR 01-03-108, filed 1/22/01, effective 1/22/01)

WAC 246-887-100   Schedule I.   The board finds that the following substances have high potential for abuse and have no accepted medical use in treatment in the United States or that they lack accepted safety for use in treatment under medical supervision. The board, therefore, places each of the following substances in Schedule I.

     (a) The controlled substances listed in this section, by whatever official name, common or usual name, chemical name, or brand name, are included in Schedule I.

     (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

     (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

     (2) Acetylmethadol;

     (3) Allylprodine;

     (4) Alphacetylmethadol; (([(except for levo-alphacetylmethadol - also known as levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);])) (except for levo-alphacetylmethadol - Also known as levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);

     (5) Alphameprodine;

     (6) Alphamethadol;

     (7) Alpha-methylfentanyl (N-[1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

     (8) Benzethidine;

     (9) Betacetylmethadol;

     (10) Betameprodine;

     (11) Betamethadol;

     (12) Betaprodine;

     (13) Clonitazene;

     (14) Dextromoramide;

     (15) Diampromide;

     (16) Diethylthiambutene;

     (17) Difenoxin;

     (18) Dimenoxadol;

     (19) Dimepheptanol;

     (20) Dimethylthiambutene;

     (21) Dioxaphetyl butyrate;

     (22) Dipipanone;

     (23) Ethylmethylthiambutene;

     (24) Etonitazene;

     (25) Etoxeridine;

     (26) Furethidine;

     (27) Gamma-hydroxybutyric Acid (other names include: GHB);

     (28) Hydroxypethidine;

     (29) Ketobemidone;

     (30) Levomoramide;

     (31) Levophenacylmorphan;

     (32) 3-Methylfentanyl (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl)]-N-phenylpropanamide);

     (33) Morpheridine;

     (34) MPPP (1-Methyl-4-phenyl-4-propionoxypiperidine);

     (35) Noracymethadol;

     (36) Norlevorphanol;

     (37) Normethadone;

     (38) Norpipanone;

     (39) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);

     (40) Phenadoxone;

     (41) Phenampromide;

     (42) Phenomorphan;

     (43) Phenoperidine;

     (44) Piritramide;

     (45) Proheptazine;

     (46) Properidine;

     (47) Propiram;

     (48) Racemoramide;

     (49) Tilidine;

     (50) Trimeperidine.

     (c) Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1) Acetorphine;

     (2) Acetyldihydrocodeine;

     (3) Benzylmorphine;

     (4) Codeine methylbromide;

     (5) Codeine-N-Oxide;

     (6) Cyprenorphine;

     (7) Desomorphine;

     (8) Dihydromorphine;

     (9) Drotebanol;

     (10) Etorphine (except hydrochloride salt);

     (11) Heroin;

     (12) Hydromorphinol;

     (13) Methyldesorphine;

     (14) Methyldihydromorphine;

     (15) Morphine methylbromide;

     (16) Morphine methylsulfonate;

     (17) Morphine-N-Oxide;

     (18) Myrophine;

     (19) Nicocodeine;

     (20) Nicomorphine;

     (21) Normorphine;

     (22) Pholcodine;

     (23) Thebacon.

     (d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of paragraph (d) of this section, only, the term "isomer" includes the optical, position, and geometric isomers):

     (1) 4-bromo-2,5-dimethoxy-amphetamine: Some trade or other names: 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA;

     (2) 2,5-dimethoxyamphetamine: Some trade or other names: 2,5-dimethoxy-a-methylphenethylamine; 2,5-DMA;

     (3) 2,5-dimethoxy-4-ethylamphetamine (DOET)

     (4) 4-methoxyamphetamine: Some trade or other names: 4-methoxy-a-methylphenethylamine; paramethoxyamphetamine, PMA;

     (5) 5-methoxy-3,4-methylenedioxy-amphetamine;

     (6) 4-methyl-2,5-dimethoxy-amphetamine: Some trade and other names: 4-methyl-2,5-dimethoxy-a-methylphenethylamine; "DOM"; and "STP";

     (7) 3,4-methylenedioxy amphetamine;

     (8) 3,4-methylenedioxymethamphetamine (MDMA);

     (9) 3,4,5-trimethoxy amphetamine;

     (10) Bufotenine: Some trade or other names: 3-(beta-Dimethylaminoethyl)-5-hydroxindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;

     (11) Diethyltryptamine: Some trade or other names: N,N-Diethyltryptamine; DET;

     (12) Dimethyltryptamine: Some trade or other names: DMT;

     (13) Ibogaine: Some trade or other names: 7-Ethyl-6,6 beta,7,8,9,10,12,13,-octahydro-2-methoxy-6,9methano-5H-pyndo (1',2':1,2) azepino (5,4-b) indole; Tabernanthe iboga;

     (14) Lysergic acid diethylamide;

     (15) Marihuana;

     (16) Mescaline;

     (17) Parahexyl-7374; some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo[b,d]pyran; synhexyl;

     (18) Peyote, meaning all parts of the plant presently classified botanically as Lophophora Williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds, or extracts; (interprets 21 USC § 812 (c), Schedule I (c)(12))

     (19) N-ethyl-3-piperidyl benzilate;

     (20) N-methyl-3-piperidyl benzilate;

     (21) Psilocybin;

     (22) Psilocyn;

     (23) Any of the following synthetic cannabimimetics, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (i) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, and AM-2201;

     (ii) Naphthylmethylindoles: Any compound containing a1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199;

     (iii) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307;

     (iv) Naphthylmethylindenes: Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176;

     (v) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;

     (vi) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol, and CP 47,497;

     (vii) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;

     (viii) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de]-[1,4-benzoxazin-6-yl]-1-napthalenylmethanone: Some trade or other names: WIN 55,212-2.

     (24) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp., and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following:

     (i) Delta 1 - cis - or transtetrahydrocannabinol, and their optical isomers, excluding tetrahydrocannabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration;

     (ii) Delta 6 - cis - or transtetrahydrocannabinol, and their optical isomers;

     (iii) Delta 3,4 - cis - or transtetrahydrocannabinol, and its optical isomers;

     (iv) (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c]chromen-1-ol: Some trade or other names: HU-210.

(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)

     (((24))) (25) Ethylamine analog of phencyclidine: Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

     (((25))) (26) Pyrrolidine analog of phencyclidine: Some trade or other names: 1-(1-phencyclohexyl)pyrrolidine; PCPy; PHP;

     (((26))) (27) Thiophene analog of phencyclidine: Some trade or other names: 1-(1-[2-thenyl]-cyclohexly)-pipendine; 2-thienylanalog of phencyclidine; TPCP; TCP;

     (e) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (i) Mecloqualone;

     (ii) Methaqualone.

     (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

     (((i))) (1) Cathinone (also known as 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone and norephedrone);

     (((ii))) (2) 4-Fluoromethcathinone (Flephedrone);

     (3) Beta-keto-N-Methylbenzodioxolylpropylamine (bk-MBDB, Butylone);

     (4) 3,4-Methylenedioxymethcathinone (Methylone);

     (5) 3,4-Methylenedioxypyrovalerone (MDPV);

     (6) 4-Methylmethcathinone (Mephedrone);

     (7) Fenethylline;

     (((iii))) (8) N-ethylamphetamine;

     (((iv))) (9) 4-methylaminorex;

     (((v))) (10) N,N-dimethylamphetamine.

[01-03-108, § 246-887-100, filed 1/22/01, effective 1/22/01. Statutory Authority: RCW 18.64.005. 94-08-098, § 246-887-100, filed 4/6/94, effective 5/7/94. Statutory Authority: RCW 18.65.005 and 18.64.005. 94-07-105, § 246-887-100, filed 3/18/94, effective 3/18/94. Statutory Authority: RCW 18.64.005. 92-04-029 (Order 239B), § 246-887-100, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. 91-18-057 (Order 191B), recodified as § 246-887-100, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. 89-17-023 (Order 226), § 360-36-410, filed 8/8/89, effective 9/8/89; 86-16-057 (Order 200), § 360-36-410, filed 8/1/86. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. 84-22-062 (Order 190), § 360-36-410, filed 11/7/84.]

     Reviser's note: The brackets and enclosed material in the text of the above section occurred in the copy filed by the agency and appear in the Register pursuant to the requirements of RCW 34.08.040.

© Washington State Code Reviser's Office